Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) insider Gopi Shankar acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was bought at an average cost of $2.71 per share, for a total transaction of $13,550.00. Following the completion of the purchase, the insider directly owned 81,443 shares in the company, valued at $220,710.53. This represents a 6.54% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Larimar Therapeutics Price Performance
LRMR traded down $0.03 on Thursday, hitting $2.70. The company had a trading volume of 1,190,176 shares, compared to its average volume of 2,378,292. The company’s fifty day moving average price is $2.97 and its 200 day moving average price is $3.77. Larimar Therapeutics, Inc. has a 1-year low of $1.91 and a 1-year high of $6.42. The stock has a market cap of $280.48 million, a price-to-earnings ratio of -1.38 and a beta of 0.73.
Hedge Funds Weigh In On Larimar Therapeutics
Institutional investors have recently made changes to their positions in the business. AIGH Capital Management LLC bought a new position in Larimar Therapeutics in the 3rd quarter worth approximately $5,911,000. WINTON GROUP Ltd acquired a new position in Larimar Therapeutics during the 2nd quarter valued at $160,000. Engineers Gate Manager LP acquired a new position in Larimar Therapeutics during the 2nd quarter valued at $69,000. Integrated Wealth Concepts LLC bought a new stake in Larimar Therapeutics in the 2nd quarter valued at $27,000. Finally, Squarepoint Ops LLC bought a new stake in Larimar Therapeutics in the 2nd quarter valued at $346,000. 91.92% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
View Our Latest Research Report on LRMR
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Recommended Stories
- Five stocks we like better than Larimar Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
